When it comes to 3D bioprinting, there is no doubt that there will be billions of dollars made over the coming decade within the space. As the technology advances, so too will the sheer number of possible applications. From drug toxicity testing to the eventual bio-fabrication of actual human organs, 3D printing will be a key driver of future medical innovations. These potential innovations, many of which could change the way we deal with a variety of both common and uncommon ailments, are what will surely spark additional R&D funding.
Back in April, we got word that L’Oréal USA & Organovo would team to further the research and development taking place within the space, specifically for the creation of 3D printable skin. When a big name like L’Oréal enters the space, other companies, researchers and investors take note. Today an even bigger name will be entering the bio-printing space in hopes of discovering useful applications for this incredible technology.
Procter & Gamble, the 177-year-old American consumer goods company, headquartered in Cincinnati, Ohio, will be launching a major grant competition in Singapore. As a part of this competition they will be asking academics to explore ideas in which their company can use bio-printing in a beneficial and profitable way. The compeition will be open to any one of the numerous research institutions within Singapore and the company hopes it will spur on ideas for the technology which may have otherwise been overlooked.
“We want to look at the possibilities of bioprinting. It’s definitely a very strong emerging area,” said Professor Elena Lurie-Luke, the head of P&G’s Global Life Sciences Open Innovation business.
This latest grant by P&G is part of an initiative being worked on with the Singapore government’s Agency for Science, Technology and Research (A*STAR), which is worth $60m over a five-year period.
“There’s a lot of interest from both consumer goods companies and big pharma in bioprinting. P&G’s strategy to launch a grant competition is probably a very cost effective way of trying to get a snapshot of all the possibilities,” stated Brian Derby, professor of materials science at the University of Manchester.
With companies such as Organovo pushing forward on numerous bio-printing fronts, it will be interesting to see just how quickly P&G is able to move forward with future bio-printing applications. The company certainly has deep pockets and if provided with the right ideas could substantially move the 3D bio-printing needle forward considerably over the next few years. Stay tuned for further details in regards to this compeition, and let us know your thoughts on P&G’s pseudo-entrance into the space. Discuss in the Procter & Gamble 3D Bio-printing forum thread on 3DPB.com.
You May Also Like
New Partnership: BEGO’s Dental Materials Allow Formlabs Customers to 3D Print Crowns & Bridges
BEGO, headquartered in Germany, has been a leader in the dental field for 130 years—and as pioneers in 3D printing for the last two decades, they now specialize in all...
Structo & pro3dure Partnering: Dental Customers Benefit from Expansion of Materials for Velox Ecosystem
Innovative materials once again merge with 3D printing hardware in an international collaboration as Structo announces a partnership with pro3dure to jointly offer products for the dental industry. Structo is...
Shapeways Adopts Envision One cDLM 3D Printing with Henkel Materials
Shapeways, Henkel and EnvisionTEC have put out a video demonstrating the possibilities of a such a three-way partnership. While Shapeways is an expert at providing 3D printing services for its...
More 3D Printing Speakers Lined Up for Next Month’s Additive Manufacturing Strategies
Next month, February 11th through 12th, the third annual Additive Manufacturing Strategies summit, co-hosted by 3DPrint.com and SmarTech Analysis, is returning to Boston for its 2020 edition. The Early Bird registration...
View our broad assortment of in house and third party products.